GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2026)

GoodRx Holdings has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $21.8 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.21% year-over-year to $21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.1 million (up 15.56% YoY) and the FY2025 annual result came in at $85.2 million, up 22.55% from the prior year.
• Depreciation & Amortization (CF) eased to $21.8 million in Q1 2026 per GDRX's latest filing, from $23.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $43.6 million in Q4 2023 and troughed at $11.4 million in Q1 2022.
• A 5-year average of $19.9 million and a median of $17.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 180.74% in 2023, then plunged 56.21% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $15.5 million in 2022, then soared by 180.74% to $43.6 million in 2023, then slumped by 56.21% to $19.1 million in 2024, then advanced by 21.21% to $23.1 million in 2025, then declined by 5.85% to $21.8 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $21.8 million, $23.1 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.